陕企研发的1类创新药进入国家医保药品目录

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the inclusion of 50 Class 1 innovative drugs in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) [1] - The drug Mesylate Prefofovir Tablets (brand name: Xinshi Mu) developed by Xi'an Xintong Pharmaceutical Research Co., Ltd. is the only Class 1 innovative drug from Shaanxi Province to be included, effective from January 1, 2026 [1] Group 1: Drug Details - Class 1 innovative drugs are defined as drugs that have not been marketed domestically or internationally, representing the highest level of drug innovation in China's registration classification [1] - Mesylate Prefofovir Tablets are indicated for the treatment of adult chronic hepatitis B, utilizing liver-targeted delivery technology to achieve precise release of active ingredients in the liver [1] - The drug significantly reduces the safety risks associated with kidneys and bones compared to conventional treatment options while effectively inhibiting hepatitis B virus replication [1] Group 2: Market Impact - Clinical research indicates that Mesylate Prefofovir Tablets excel in reducing hepatitis B surface antigen levels, which may enhance clinical cure rates and lower the long-term risks of cirrhosis and liver cancer [2] - The inclusion of this drug in the national medical insurance catalog is expected to rapidly increase its market availability, improving accessibility for a large number of chronic hepatitis B patients in China [2] - The influence of Shaanxi's listed backup enterprises in the capital market is anticipated to expand, with ongoing efforts to enhance support mechanisms for strategic emerging industries like biomedicine [2]